Catalyst Pharmaceuticals, Inc. announced that the FTC granted early termination of the HSR Act waiting period for its merger with Angelini Pharma S.p.A. and Angelini Cielo Inc. The transaction is expected to close in the third quarter of 2026, pending stockholder approval and other customary closing conditions. Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare neurological diseases.
